| Aug 9 |
ARS stock jumps 13% on FDA approval of epinephrine nasal spray (update)
|
| Aug 9 |
ARS Pharmaceuticals' Neffy Nasal Spray Approved by FDA for Type I Allergic Reactions
|
| Aug 9 |
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
|
| Aug 9 |
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
|
| Aug 7 |
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
|
| Aug 6 |
ARS Pharmaceuticals GAAP EPS of -$0.13 misses by $0.02, revenue of $0.5M misses by $0.17M
|
| Aug 6 |
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 6 |
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
|
| Aug 1 |
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
|
| Jul 25 |
US Growth Companies With Insider Ownership As High As 31%
|
